Topical Dorzolamide for Idiopathic Macular Hole

INTERVENTION: In this double blinded study, those randomised to treatment will receive 2% dorzolamide drops to the eye three times per day for 8 weeks. Drops will be self administered by the patient following detailed instruction and will not be supervised. CONDITION: Eye ‐ Diseases / disorders of the eye Idiopathic macular hole; ; Idiopathic macular hole PRIMARY OUTCOME: Closure of macular hole as assessed with optical coherence tomography[8 weeks post initiation of treatment.] SECONDARY OUTCOME: Central retinal thickness as assessed with optical coherence tomography[8 weeks post initiation of treatment.] Visual acuity measured in letters using an ETDRS chart[8 weeks post initiation of treatment.] INCLUSION CRITERIA: Ability to provide informed consent and complete study assessments Age 18 years or older Idiopathic macular hole in study eye